Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials
- 19 November 2009
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (5), 1883-1897
- https://doi.org/10.1021/jm900743c
Abstract
No abstract availableThis publication has 130 references indexed in Scilit:
- Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in ratsNuclear Medicine and Biology, 2009
- Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood−Brain BarrierJournal of Medicinal Chemistry, 2009
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomographyEpilepsia, 2009
- Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patientsCell and tissue research, 2008
- Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorptionAdvanced Drug Delivery Reviews, 2008
- Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSAJournal of Neural Transmission, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Role of multidrug resistance protein 2 (MRP2) in glutathione‐bimane efflux from Caco‐2 and rat renal proximal tubule cellsBritish Journal of Pharmacology, 2001